Neuropeptides in drug research

David Poyner*, Helen Cox, Mark Bushfield, J. Mark Treherne, Melissa K. Demetrikopoulos

*Corresponding author for this work

Research output: Chapter in Book/Published conference outputChapter (peer-reviewed)peer-review


Neuropeptides have been a subject of considerable interest in the pharmaceutical industry over the last 20 years or more. Many drug discovery teams have contributed to our understanding of neuropeptide biology but no significant drugs that act selectively upon neuropeptide receptors have yet emerged from the clinic. There are, however, a plethora of clinically useful drugs that act at other classes of neurotransmitter and neuromodulator receptors, many of them discovered over the last 20 years. Nevertheless, we think that the future for the discovery of novel drugs acting at neuropeptide receptors looks bright for two reasons: (1) there has been a substantial increase in our understanding of the function of neuropeptides; and (2) high-throughput screening (HTS) against neuropeptide receptors has now begun to yield many interesting drug-like molecules, rather than peptides, that have the potential to become clinically useful drugs. 

Original languageEnglish
Title of host publicationProgress in Drug Research
EditorsErnst Junker
Place of PublicationCham, Switzerland
Number of pages29
ISBN (Electronic)978-3-0348-8391-7
ISBN (Print)978-3-7643-6113-6, 978-3-0348-9546-0
Publication statusPublished - 2000

Publication series

NameProgress in Drug Research
PublisherBirkhauser Verlag Basel
ISSN (Print)0071-786X


  • Calcitonin gene-related peptide (CGRP)
  • Central nervous system
  • Cholecystokinin
  • Galanin
  • Neuropeptide Y
  • Neuropeptides
  • Opioid peptides
  • Peripheral nervous system
  • Substance P


Dive into the research topics of 'Neuropeptides in drug research'. Together they form a unique fingerprint.

Cite this